Methotrexate: clinical pharmacology, current status and therapeutic guidelines†
References (99)
- et al.
Blood
(1971) - et al.
Blood
(1975) - et al.
Eur. J. Cancer
(1972) - et al.
Europ. J. Cancer
(1966) - et al.
Biochem. Med.
(1971) - et al.
Am. J. Obstet. Gynec.
(1972) - et al.
Lancet
(1972) - et al.
J. Pediat.
(1976) - et al.
Biochem. Pharm.
(1972) JAMA
(1969)
Cancer Res.
Science
Cancer Res
Cancer Res
Nature
N. Engl. J. Med.
Cancer Res
Trans. Am. neurol. Ass.
Cancer Chemother. Rep.
Am. intern. Med.
Nature
J. clin. Invest.
Cancer Chemother. Rep.
Cancer
Br. J. Cancer
Cancer Res
Cancer
Lancet
Cancer
New Engl. J. Med.
Cancer
J. Natl. Cancer Inst.
Ann. N. Y. Acad. Sci.
Mol. Pharmacol.
Br. J. Cancer
Cancer Res
Cancer
Br. Med. J.
Clin. Pharmac. Ther.
Cited by (176)
External evaluation and systematic review of population pharmacokinetic models for high-dose methotrexate in cancer patients
2023, European Journal of Pharmaceutical SciencesIdentification and pharmacological modification of resistance mechanisms to protoporphyrin-mediated photodynamic therapy in human cutaneous squamous cell carcinoma cell lines
2022, Photodiagnosis and Photodynamic TherapyFixed-Dose Glucarpidase for Toxic Methotrexate Levels and Acute Kidney Injury in Adult Lymphoma Patients: Case Series
2021, Clinical Lymphoma, Myeloma and LeukemiaCitation Excerpt :After receipt of HDMTX, 83% of the parent drug and its active metabolites are eliminated by the kidney via glomerular filtration with some contribution from tubular secretion.9 Prolonged exposure to toxic serum MTX (sMTX) levels (> 5-10 μmol/L at 24 hours, > 1 μmol/L at 48 hours, or > 0.1 μmol/L at 72 hours) are linked to increased risk of nephrotoxicity and life-threatening toxicities such as stomatitis, prolonged myelosuppression, dermatitis and hepatotoxicity.10-12 Before the approval of glucarpidase (GPDG2), strategies for MTX removal in the setting of kidney dysfunction included prompt initiation of extracorporeal therapies (ECT).8,13
Analytical methodologies for determination of methotrexate and its metabolites in pharmaceutical, biological and environmental samples
2019, Journal of Pharmaceutical AnalysisCitation Excerpt :The most important side effects of MTX treatment are hematologic, hepatic, gastrointestinal, and mucosal events. In addition, high doses of MTX might induce kidney injury due to crystallization of the parent drug and the metabolites in the nephrons, and the retardation of renal elimination leads to systemic toxicity [33]. As sample preparation is often the rate-limiting and labor-intensive step of the whole analytical procedure, choosing an optimal technique for sample preparation is the most significant step in setting up an analytical method for the measurement of MTX in different samples.
A population pharmacokinetic model of methotrexate in Korean patients with haematologic malignancy
2024, British Journal of Clinical Pharmacology
- †
Supported, in part, by Grant Number CA 16525, awarded by the National Cancer Institute, Department of Health, Education and Welfare.